Friday, July 10, 2026

pharma · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · metastatic or unresectable, recurrent HNSCC

Createrna Science and

Wuhan Createrna Science is a pharma organization headquartered in London, GB. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, metastatic or unresectable, recurrent HNSCC,

shanghai, CN, London HQ
26 Employees
NMPA registrant Type
Company details
Status
Public
HQ
shanghai, CN, London
Employees
26
Programs
51
Drugs
87
Patents
0

Quick answer

Wuhan Createrna Science is a pharma organization headquartered in London, GB. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, metastatic or unresectable, recurrent HNSCC, Dry Eye Disease, Type 2 diabetes mellitus, Advanced cutaneous melanoma and Advanced mucosal melanoma. NovaPharmaNews links 51 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (30), phase 3 (13), approved (5).

Company snapshot

Createrna Science and maintains 51 tracked programs across Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, metastatic or unresectable, recurrent HNSCC, Dry Eye Disease, Type 2 diabetes mellitus, Advanced cutaneous melanoma and Advanced mucosal melanoma, Primary Immune Thrombocytopenia, Basket tumors, Burkitt lymphoma, Mantle cell lymphoma, Chronic Hepatitis B, Low back pain, newly diagnos

  • 51 active pipeline program(s) linked via ClinicalTrials.gov.
  • 51 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Createrna Science and. Not investment advice.

Lead pipeline drugs

Active clinical programs

  • AC-203-EBS-007 Generalized Epidermolysis Bullosa Simplex (EBS)
    Phase 3
  • ALKS 4230-007 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Phase 3
  • AT148006 Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
    Phase 3
  • BASICstudy Chronic cluster headache
    Phase 3

Momentum

Proprietary activity score for Createrna Science and.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Createrna Science and.

  1. Clinical update

    TRIO041 — Phase 3

  2. Clinical update

    AT148004 — Phase 2

  3. Clinical update

    AT148003 — Phase 2

  4. Clinical update

    LY06006/MRCT-301 — Phase 3

  5. Clinical update

    BTIIMD-03-EC-23-DISC — Approved

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Createrna Science and?

    Wuhan Createrna Science is a pharma organization headquartered in London, GB. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, metastatic or unresectable, recurrent HNSCC, Dry Eye Disease, Type 2 diabetes mellitus, Advanced cutaneou

  • Is Createrna Science and publicly traded?

    Createrna Science and appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Createrna Science and develop or market?

    We link 87 drug profile(s) where Createrna Science and is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ology-bioservices-ireland-ltd#company-drugs.

  • What are the latest developments for Createrna Science and?

    In the last 12 months our linked public records show 51 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Createrna Science and focus on?

    Createrna Science and focuses on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, metastatic or unresectable, recurrent HNSCC, Dry Eye Disease based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
84
Oncology
11
Infectious Disease
3
Immunology
1
Neurology
1
Related companies